Aurenar wins breakthrough designation for cerebral vasospasm neuromodulation platform

Aurenar’s V-Link system uses transauricular vagus nerve stimulation to modulate brain inflammation in patients that have experienced a stroke. Aurenar’s V-Link system uses transauricular vagus nerve stimulation to modulate brain inflammation in patients that have experienced a stroke. Research indicates that cerebral vasospasm occurs in 40%-70% of aSAH patients. Credit: II.studio/Shutterstock.com The US Food and Drug Administration (FDA) has granted breakthrough device designation to Aurenar’s V-Link system for cerebral vasospasm treatment in adults following stroke. Cerebral vasospasm, a key mechanism of delayed cerebral ischemia (DCI), is a common complication wherein blood vessels in the brain constrict in the days following…

Source: Medical Device Network